NGF and cardiac arrest: As briefly anticipated before, in a 2023 prospective case series, a combined treatment approach using intranasal human recombinant NGF (hr-NGF) and ten sessions (one session per day for 10 consecutive days) of 20-minute anodal tDCS to the left dorsolateral prefrontal cortex (DLPF) has been studied, and showed significantly improved functional, electrophysiological, and clinical outcomes in children in a chronic vegetative state following prolonged out-of-hospital cardiac arrest [164].